Inhibition of JAKs in macrophages increases lipopolysaccharide-induced cytokine production by blocking IL-10-mediated feedback

Journal of Immunology

Volumn 189, Issue 6, 2012, Pages 2784-2792

  Pattison, Michael J ^a   MacKenzie, Kirsty F ^a   Arthur, J Simon C ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; JANUS KINASE; LIPOPOLYSACCHARIDE; RUXOLITINIB; STAT1 PROTEIN; TOFACITINIB; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ARTICLE; BONE MARROW; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME INHIBITION; LYMPHOCYTE ACTIVATION; MACROPHAGE; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; BONE MARROW CELLS; CELLS, CULTURED; CYTOKINES; FEEDBACK; INFLAMMATION MEDIATORS; INTERFERON TYPE I; INTERLEUKIN-10; JANUS KINASES; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; PYRAZOLES; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; UP-REGULATION;

EID: 84866166941     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1200310     Document Type: Article

References (54)

1. Schindler, C., D. E. Levy, and T. Decker. 2007. JAK-STAT signaling: from interferons to cytokines. J. Biol. Chem. 282: 20059-20063. (Pubitemid 47099977)
2. Levy, D. E., and J. E. Darnell, Jr. 2002. Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 3: 651-662. (Pubitemid 34987786)
3. Quintás-Cardama, A., H. Kantarjian, J. Cortes, and S. Verstovsek. 2011. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat. Rev. Drug Discov. 10: 127-140.
4. Yu, H., D. Pardoll, and R. Jove. 2009. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9: 798-809.
5. Vijayakrishnan, L., R. Venkataramanan, and P. Gulati. 2011. Treating inflammation with the Janus kinase inhibitor CP-690,550. Trends Pharmacol. Sci. 32: 25-34.
6. Ghoreschi, K., A. Laurence, and J. J. O'Shea. 2009. Janus kinases in immune cell signaling. Immunol. Rev. 228: 273-287.
7. Changelian, P. S., M. E. Flanagan, D. J. Ball, C. R. Kent, K. S. Magnuson, W. H. Martin, B. J. Rizzuti, P. S. Sawyer, B. D. Perry, W. H. Brissette, et al. 2003. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302: 875-878. (Pubitemid 37339629)
8. Quintás-Cardama, A., K. Vaddi, P. Liu, T. Manshouri, J. Li, P. A. Scherle, E. Caulder, X. Wen, Y. Li, P. Waeltz, et al. 2010. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115: 3109-3117.
9. Macchi, P., A. Villa, S. Giliani, M. G. Sacco, A. Frattini, F. Porta, A. G. Ugazio, J. A. Johnston, F. Candotti, J. J. O'Shea, et al. 1995. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 377: 65-68.
10. Williams, N. K., R. S. Bamert, O. Patel, C. Wang, P. M. Walden, A. F. Wilks, E. Fantino, J. Rossjohn, and I. S. Lucet. 2009. Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. J. Mol. Biol. 387: 219-232.
11. Jiang, J. K., K. Ghoreschi, F. Deflorian, Z. Chen, M. Perreira, M. Pesu, J. Smith, D. T. Nguyen, E. H. Liu, W. Leister, et al. 2008. Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl- 3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl) -3-oxopropanenitrile (CP-690,550). J. Med. Chem. 51: 8012-8018.
12. Garber, K. 2011. Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis. Nat. Biotechnol. 29: 467-468.
13. Verstovsek, S., H. Kantarjian, R. A. Mesa, A. D. Pardanani, J. Cortes-Franco, D. A. Thomas, Z. Estrov, J. S. Fridman, E. C. Bradley, S. Erickson-Viitanen, et al. 2010. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N. Engl. J. Med. 363: 1117-1127.
14. Takeuchi, O., and S. Akira. 2010. Pattern recognition receptors and inflammation. Cell 140: 805-820.
15. Liew, F. Y., D. Xu, E. K. Brint, and L. A. O'Neill. 2005. Negative regulation of Toll-like receptor-mediated immune responses. Nat. Rev. Immunol. 5: 446-458. (Pubitemid 40835033)
16. Serhan, C. N., S. D. Brain, C. D. Buckley, D. W. Gilroy, C. Haslett, L. A. O'Neill, M. Perretti, A. G. Rossi, and J. L. Wallace. 2007. Resolution of inflammation: state of the art, definitions and terms. FASEB J. 21: 325-332. (Pubitemid 46213480)
17. O'Neill, L. A. 2008. When signaling pathways collide: positive and negative regulation of Toll-like receptor signal transduction. Immunity 29: 12-20. (Pubitemid 351952460)
18. Kühn, R., J. Löhler, D. Rennick, K. Rajewsky, and W. Müller. 1993. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75: 263-274. (Pubitemid 23320290)
19. Fiorentino, D. F., A. Zlotnik, T. R. Mosmann, M. Howard, and A. O'Garra. 1991. IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147: 3815-3822.
20. Ananieva, O., J. Darragh, C. Johansen, J. M. Carr, J. McIlrath, J. M. Park, A. Wingate, C. E. Monk, R. Toth, S. G. Santos, et al. 2008. The kinases MSK1 and MSK2 act as negative regulators of Toll-like receptor signaling. Nat. Immunol. 9: 1028-1036.
21. Kim, C., Y. Sano, K. Todorova, B. A. Carlson, L. Arpa, A. Celada, T. Lawrence, K. Otsu, J. L. Brissette, J. S. Arthur, and J. M. Park. 2008. The kinase p38α serves cell type-specific inflammatory functions in skin injury and coordinates pro- and anti-inflammatory gene expression. Nat. Immunol. 9: 1019-1027.
22. Darragh, J., O. Ananieva, A. Courtney, S. Elcombe, and J. S. Arthur. 2010. MSK1 regulates the transcription of IL-1ra in response to TLR activation in macrophages. Biochem. J. 425: 595-602.
23. Fiorentino, D. F., M. W. Bond, and T. R. Mosmann. 1989. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J. Exp. Med. 170: 2081-2095.
24. Murray, P. J. 2006. Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response. Curr. Opin. Pharmacol. 6: 379-386.
25. Takeda, K., B. E. Clausen, T. Kaisho, T. Tsujimura, N. Terada, I. Förster, and S. Akira. 1999. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10: 39-49. (Pubitemid 29077382)
26. El Kasmi, K. C., A. M. Smith, L. Williams, G. Neale, A. D. Panopoulos, S. S. Watowich, H. Häcker, B. M. Foxwell, and P. J. Murray. 2007. Cutting edge: a transcriptional repressor and corepressor induced by the STAT3-regulated antiinflammatory signaling pathway. J. Immunol. 179: 7215-7219.
27. Smith, A. M., J. E. Qualls, K. O'Brien, L. Balouzian, P. F. Johnson, S. Schultz-Cherry, S. T. Smale, and P. J. Murray. 2011. A distal enhancer in Il12b is the target of transcriptional repression by the STAT3 pathway and requires the B-ZIP protein NFIL-3. J. Biol. Chem. 286: 23582-23590.
28. Bain, J., L. Plater, M. Elliott, N. Shpiro, C. J. Hastie, H. McLauchlan, I. Klevernic, J. S. Arthur, D. R. Alessi, and P. Cohen. 2007. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 408: 297-315.
29. Beardmore, V. A., H. J. Hinton, C. Eftychi, M. Apostolaki, M. Armaka, J. Darragh, J. McIlrath, J. M. Carr, L. J. Armit, C. Clacher, et al. 2005. Generation and characterization of p38β (MAPK11) gene-targeted mice. Mol. Cell. Biol. 25: 10454-10464. (Pubitemid 41681967)
30. Carl, V. S., J. K. Gautam, L. D. Comeau, and M. F. Smith, Jr. 2004. Role of endogenous IL-10 in LPS-induced STAT3 activation and IL-1 receptor antagonist gene expression. J. Leukoc. Biol. 76: 735-742. (Pubitemid 39129108)
31. Gleason, C. E., A. Ordureau, R. Gourlay, J. S. Arthur, and P. Cohen. 2011. Polyubiquitin binding to optineurin is required for optimal activation of TANK-binding kinase 1 and production of interferon β. J. Biol. Chem. 286: 35663-35674.
32. Ho, H. H., and L. B. Ivashkiv. 2006. Role of STAT3 in type I interferon responses: negative regulation of STAT1-dependent inflammatory gene activation. J. Biol. Chem. 281: 14111-14118. (Pubitemid 43848338)
33. Thomas, K. E., C. L. Galligan, R. D. Newman, E. N. Fish, and S. N. Vogel. 2006. Contribution of interferon-β to the murine macrophage response to the Toll-like receptor 4 agonist, lipopolysaccharide. J. Biol. Chem. 281: 31119- 31130.
34. Toshchakov, V., B. W. Jones, P. Y. Perera, K. Thomas, M. J. Cody, S. Zhang, B. R. Williams, J. Major, T. A. Hamilton, M. J. Fenton, and S. N. Vogel. 2002. TLR4, but not TLR2, mediates IFN-β-induced STAT1α/β- dependent gene expression in macrophages. Nat. Immunol. 3: 392-398. (Pubitemid 34308628)
35. Platzer, C., E. Fritsch, T. Elsner, M. H. Lehmann, H. D. Volk, and S. Prösch. 1999. Cyclic adenosine monophosphate-responsive elements are involved in the transcriptional activation of the human IL-10 gene in monocytic cells. Eur. J. Immunol. 29: 3098-3104. (Pubitemid 29484199)
36. Alvarez, Y., C. Municio, S. Alonso, M. Sánchez Crespo, and N. Fernández. 2009. The induction of IL-10 by zymosan in dendritic cells depends on CREB activation by the coactivators CREB-binding protein and TORC2 and autocrine PGE2. J. Immunol. 183: 1471-1479.
37. Tone, M., M. J. Powell, Y. Tone, S. A. Thompson, and H. Waldmann. 2000. IL-10 gene expression is controlled by the transcription factors Sp1 and Sp3. J. Immunol. 165: 286-291. (Pubitemid 30429518)
38. Brightbill, H. D., S. E. Plevy, R. L. Modlin, and S. T. Smale. 2000. A prominent role for Sp1 during lipopolysaccharide-mediated induction of the IL-10 promoter in macrophages. J. Immunol. 164: 1940-1951. (Pubitemid 30108749)
39. Chakrabarti, A., A. J. Sadler, N. Kar, H. A. Young, R. H. Silverman, and B. R. Williams. 2008. Protein kinase R-dependent regulation of interleukin-10 in response to double-stranded RNA. J. Biol. Chem. 283: 25132-25139.
40. Cao, S., X. Zhang, J. P. Edwards, and D. M. Mosser. 2006. NF-κB1 (p50) homodimers differentially regulate pro- and anti-inflammatory cytokines in macrophages. J. Biol. Chem. 281: 26041-26050. (Pubitemid 44401810)
41. Gao, J. J., M. B. Filla, M. J. Fultz, S. N. Vogel, S. W. Russell, and W. J. Murphy. 1998. Autocrine/paracrine IFN-αβ mediates the lipopolysaccharide-induced activation of transcription factor Stat1alpha in mouse macrophages: pivotal role of Stat1α in induction of the inducible nitric oxide synthase gene. J. Immunol. 161: 4803-4810. (Pubitemid 28492057)
42. Kawai, T., O. Takeuchi, T. Fujita, J. Inoue, P. F. Mühlradt, S. Sato, K. Hoshino, and S. Akira. 2001. Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J. Immunol. 167: 5887- 5894.
43. Stumhofer, J. S., J. S. Silver, A. Laurence, P. M. Porrett, T. H. Harris, L. A. Turka, M. Ernst, C. J. Saris, J. J. O'Shea, and C. A. Hunter. 2007. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat. Immunol. 8: 1363-1371. (Pubitemid 350131173)
44. Ziegler-Heitbrock, L., M. Lötzerich, A. Schaefer, T. Werner, M. Frankenberger, and E. Benkhart. 2003. IFN-α induces the human IL-10 gene by recruiting both IFN regulatory factor 1 and Stat3. J. Immunol. 171: 285-290. (Pubitemid 36745299)
45. Guarda, G., M. Braun, F. Staehli, A. Tardivel, C. Mattmann, I. Förster, M. Farlik, T. Decker, R. A. Du Pasquier, P. Romero, and J. Tschopp. 2011. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 34: 213-223.
46. Iyer, S. S., A. A. Ghaffari, and G. Cheng. 2010. Lipopolysaccharide- mediated IL-10 transcriptional regulation requires sequential induction of type I IFNs and IL-27 in macrophages. J. Immunol. 185: 6599-6607.
47. Staples, K. J., T. Smallie, L. M. Williams, A. Foey, B. Burke, B. M. Foxwell, and L. Ziegler-Heitbrock. 2007. IL-10 induces IL-10 in primary human monocyte-derived macrophages via the transcription factor Stat3. J. Immunol. 178: 4779-4785. (Pubitemid 46595259)
48. Gautier, G., M. Humbert, F. Deauvieau, M. Scuiller, J. Hiscott, E. E. Bates, G. Trinchieri, C. Caux, and P. Garrone. 2005. A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J. Exp. Med. 201: 1435-1446. (Pubitemid 40664087)
49. Yasuda, K., C. Richez, J. W. Maciaszek, N. Agrawal, S. Akira, A. Marshak-Rothstein, and I. R. Rifkin. 2007. Murine dendritic cell type I IFN production induced by human IgG-RNA immune complexes is IFN regulatory factor (IRF)5 and IRF7 dependent and is required for IL-6 production. J. Immunol. 178: 6876-6885. (Pubitemid 46847413)
50. Ghoreschi, K., M. I. Jesson, X. Li, J. L. Lee, S. Ghosh, J. W. Alsup, J. D. Warner, M. Tanaka, S. M. Steward-Tharp, M. Gadina, et al. 2011. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J. Immunol. 186: 4234-4243.
51. Rosengren, S., M. Corr, G. S. Firestein, and D. L. Boyle. 2012. The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon. Ann. Rheum. Dis. 71: 440-447.
52. Karaghiosoff, M., H. Neubauer, C. Lassnig, P. Kovarik, H. Schindler, H. Pircher, B. McCoy, C. Bogdan, T. Decker, G. Brem, et al. 2000. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 13: 549-560.
53. Shimoda, K., K. Kato, K. Aoki, T. Matsuda, A. Miyamoto, M. Shibamori, M. Yamashita, A. Numata, K. Takase, S. Kobayashi, et al. 2000. Tyk2 plays a restricted role in IFN α signaling, although it is required for IL-12-mediated T cell function. Immunity 13: 561-571.
54. Karaghiosoff, M., R. Steinborn, P. Kovarik, G. Kriegshäuser, M. Baccarini, B. Donabauer, U. Reichart, T. Kolbe, C. Bogdan, T. Leanderson, et al. 2003. Central role for type I interferons and Tyk2 in lipopolysaccharide- induced endotoxin shock. Nat. Immunol. 4: 471-477. (Pubitemid 36592440)